Final Rule for Generic Reporting Withdrawn

News
Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration withdrew this week its direct final rule on Reporting Information About Authorized Generic Drugs.

Rockville, MD (Feb. 12)-The US Food and Drug Administration withdrew this week its direct final rule on Reporting Information About Authorized Generic Drugs. Originally issued in September 2008 and scheduled to go into effect this week (Feb. 11, 2009), the rule was set to require drugmakers to report information on authorized generics in their annual new drug application (NDA) reports going back to 1999. The rule was part of the FDA Amendments Act (FDAAA).

As part of the September 2007 FDAAA, the agency must publish on its website a list of all authorized generic drugs included in manufacturers’ annual reports. FDA also must update the list every quarter and notify relevant federal agencies, including the Federal Trade Commission, that the list has been published. 

Under FDA’s direct final rules procedures, the receipt of any significant adverse comment will result in the withdrawal of the direct final rule, according to a written statement from the agency’s Associate Commissioner for Policy and Planning. Comments received will be considered in developing a final rule.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes